Literature DB >> 15970877

Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories.

Albert John Phillips1.   

Abstract

OBJECTIVE: This study was undertaken to investigate whether amphotericin B vaginal suppositories would be effective in the treatment of non- albicans Candida vaginitis in women who failed conventional therapy. STUDY
DESIGN: Thirty-two patients were identified with non- albicans Candida vaginitis. These patients were treated with conventional antifungal agents. Ten patients had persistence of the non- albicans Candida infection after treatment. Amphotericin B 50-mg vaginal suppositories were given nightly for 14 days to this subgroup of treatment failures.
RESULTS: Of 10 women, 8 (80%) who were treated with amphotericin B vaginally initially showed no further infection. One of the treatment successes had 2 recurrences and responded to a second course of amphotericin B but failed a third course. If this patient is considered a treatment failure, then amphotericin B vaginal suppositories were successful in 70% of patients. The medication was well tolerated and local side effects were minimal.
CONCLUSION: Amphotericin B vaginal suppositories are a viable treatment option for refractory vaginitis caused by non- albicans Candida .

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15970877     DOI: 10.1016/j.ajog.2005.03.034

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

1.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

Review 2.  Candida infections of the genitourinary tract.

Authors:  Jacqueline M Achkar; Bettina C Fries
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.

Authors:  Claire S Danby; Dina Boikov; Rina Rautemaa-Richardson; Jack D Sobel
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

Review 4.  Local treatment of vulvovaginal candidosis : general and practical considerations.

Authors:  José das Neves; Eugénia Pinto; Branca Teixeira; Gustavo Dias; Patrocínia Rocha; Teresa Cunha; Bárbara Santos; Maria H Amaral; Maria F Bahia
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Prevalence, species distribution and antifungal susceptibility of Candida albicans causing vaginal discharge among symptomatic non-pregnant women of reproductive age at a tertiary care hospital, Vietnam.

Authors:  Do Ngoc Anh; Dao Nguyen Hung; Tran Viet Tien; Vu Nhat Dinh; Vu Tung Son; Nguyen Viet Luong; Nguyen Thi Van; Nguyen Thi Nhu Quynh; Nguyen Van Tuan; Le Quoc Tuan; Nguyen Duy Bac; Nguyen Khac Luc; Le Tran Anh; Do Minh Trung
Journal:  BMC Infect Dis       Date:  2021-06-03       Impact factor: 3.090

Review 6.  Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement.

Authors:  Richard H Drew; John R Perfect
Journal:  J Fungi (Basel)       Date:  2022-02-21

7.  Amphotericin B Polymer Nanoparticles Show Efficacy against Candida Species Biofilms.

Authors:  Abdulghani Alakkad; Paul Stapleton; Corinna Schlosser; Sudaxshina Murdan; Uchechukwu Odunze; Andreas Schatzlein; Ijeoma F Uchegbu
Journal:  Pathogens       Date:  2022-01-07

8.  Recurrent Vulvovaginal Candidiasis: a Dynamic Interkingdom Biofilm Disease of Candida and Lactobacillus.

Authors:  Emily McKloud; Christopher Delaney; Leighann Sherry; Ryan Kean; Shanice Williams; Rebecca Metcalfe; Rachael Thomas; Riina Richardson; Konstantinos Gerasimidis; Christopher J Nile; Craig Williams; Gordon Ramage
Journal:  mSystems       Date:  2021-08-10       Impact factor: 6.496

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.